These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 18366309)

  • 1. Tat-specific binding IgG and disease progression in HIV type 1-infected Ugandans.
    Senkaali D; Kebba A; Shafer LA; Campbell GR; Loret EP; Van Der Paal L; Grosskurth H; Yirrell D; Kaleebu P
    AIDS Res Hum Retroviruses; 2008 Apr; 24(4):587-94. PubMed ID: 18366309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibodies to Tat and Vpr in the GRIV cohort: differential association with maintenance of long-term non-progression status in HIV-1 infection.
    Richardson MW; Mirchandani J; Duong J; Grimaldo S; Kocieda V; Hendel H; Khalili K; Zagury JF; Rappaport J
    Biomed Pharmacother; 2003 Jan; 57(1):4-14. PubMed ID: 12642031
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The absence of anti-Tat antibodies is associated with risk of disease progression in HIV-2 infection.
    Rodriguez SK; Sarr AD; Olorunnipa O; Popper SJ; Gueye-Ndiaye A; Traoré I; Dia MC; Mboup S; Kanki PJ
    J Infect Dis; 2006 Sep; 194(6):760-3. PubMed ID: 16941341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The human uniqueness of HIV: innate immunity and the viral Tat protein.
    Rodman TC; Sullivan JJ; Bai X; Winston R
    Hum Immunol; 1999 Aug; 60(8):631-9. PubMed ID: 10439309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sequence conservation and antibody cross-recognition of clade B human immunodeficiency virus (HIV) type 1 Tat protein in HIV-1-infected Italians, Ugandans, and South Africans.
    Buttò S; Fiorelli V; Tripiciano A; Ruiz-Alvarez MJ; Scoglio A; Ensoli F; Ciccozzi M; Collacchi B; Sabbatucci M; Cafaro A; Guzmán CA; Borsetti A; Caputo A; Vardas E; Colvin M; Lukwiya M; Rezza G; Ensoli B;
    J Infect Dis; 2003 Oct; 188(8):1171-80. PubMed ID: 14551888
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between different anti-Tat antibody isotypes and HIV disease progression: data from an African cohort.
    Nicoli F; Chachage M; Clowes P; Bauer A; Kowour D; Ensoli B; Cafaro A; Maboko L; Hoelscher M; Gavioli R; Saathoff E; Geldmacher C
    BMC Infect Dis; 2016 Jul; 16():344. PubMed ID: 27450538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibodies to the HIV-1 Tat protein correlated with nonprogression to AIDS: a rationale for the use of Tat toxoid as an HIV-1 vaccine.
    Zagury JF; Sill A; Blattner W; Lachgar A; Le Buanec H; Richardson M; Rappaport J; Hendel H; Bizzini B; Gringeri A; Carcagno M; Criscuolo M; Burny A; Gallo RC; Zagury D
    J Hum Virol; 1998; 1(4):282-92. PubMed ID: 10195253
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tat mutations in an African cohort that do not prevent transactivation but change its immunogenic properties.
    Campbell GR; Senkaali D; Watkins J; Esquieu D; Opi S; Yirrell DL; Kaleebu P; Loret EP
    Vaccine; 2007 Dec; 25(50):8441-7. PubMed ID: 17997200
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of distinct patterns of anti-tat antibodies in HIV-infected individuals with or without Kaposi's sarcoma.
    Demirhan I; Chandra A; Hasselmayer O; Biberfeld P; Chandra P
    J Acquir Immune Defic Syndr; 1999 Dec; 22(4):364-8. PubMed ID: 10634198
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Temporal development and prognostic value of antibody response to the major neutralizing epitopes of gp120 during HIV-1 infection.
    Turbica I; Simon F; Besnier JM; LeJeune B; Choutet P; Goudeau A; Barin F
    J Med Virol; 1997 Jul; 52(3):309-15. PubMed ID: 9210041
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of human immunodeficiency virus replication and growth advantage of CD4+ T cells from HIV-infected individuals that express intracellular antibodies against HIV-1 gp120 or Tat.
    Poznansky MC; Foxall R; Mhashilkar A; Coker R; Jones S; Ramstedt U; Marasco W
    Hum Gene Ther; 1998 Mar; 9(4):487-96. PubMed ID: 9525310
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody-Dependent Cellular Cytotoxicity-Competent Antibodies against HIV-1-Infected Cells in Plasma from HIV-Infected Subjects.
    Dupuy FP; Kant S; Barbé A; Routy JP; Bruneau J; Lebouché B; Tremblay C; Pazgier M; Finzi A; Bernard NF
    mBio; 2019 Dec; 10(6):. PubMed ID: 31848282
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibodies against full-length Tat protein and some low-molecular-weight Tat-peptides correlate with low or undetectable viral load in HIV-1 seropositive patients.
    Re MC; Vignoli M; Furlini G; Gibellini D; Colangeli V; Vitone F; La Placa M
    J Clin Virol; 2001 Apr; 21(1):81-9. PubMed ID: 11255101
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Longitudinal study of humoral immune responses in HIV type 1 subtype CRF01_AE (E)-infected Thai patients with different rates of disease progression.
    Chuenchitra T; Wasi C; Louisirirojchanakul S; Nitayaphan S; Sutthent R; Cox JH; De Souza MS; Brown AE; Birx DL; Polonis VR
    AIDS Res Hum Retroviruses; 2003 Apr; 19(4):293-305. PubMed ID: 12804005
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV-1 Tat-specific IgG antibodies in high-responders target a B-cell epitope in the cysteine-rich domain and block extracellular Tat efficiently.
    Kashi VP; Jacob RA; Paul S; Nayak K; Satish B; Swaminathan S; Satish KS; Ranga U
    Vaccine; 2009 Nov; 27(48):6739-47. PubMed ID: 19744585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapid HIV Progression Is Associated with Extensive Ongoing Somatic Hypermutation.
    Wendel BS; Fu Y; He C; Hernandez SM; Qu M; Zhang Z; Jiang Y; Han X; Xu J; Ding H; Jiang N; Shang H
    J Immunol; 2020 Aug; 205(3):587-594. PubMed ID: 32591400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationships between the presence of anti-Tat antibody, DNA and RNA viral load.
    Re MC; Gibellini D; Furlini G; Vignoli M; Vitone F; Bon I; La Placa M
    New Microbiol; 2001 Jul; 24(3):207-15. PubMed ID: 11497076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV-specific CD4-induced Antibodies Mediate Broad and Potent Antibody-dependent Cellular Cytotoxicity Activity and Are Commonly Detected in Plasma From HIV-infected humans.
    Williams KL; Cortez V; Dingens AS; Gach JS; Rainwater S; Weis JF; Chen X; Spearman P; Forthal DN; Overbaugh J
    EBioMedicine; 2015 Oct; 2(10):1464-77. PubMed ID: 26629541
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Tat subunit vaccine confers protective immunity against the immune-modulating activity of the human immunodeficiency virus type-1 Tat protein in mice.
    Agwale SM; Shata MT; Reitz MS; Kalyanaraman VS; Gallo RC; Popovic M; Hone DM
    Proc Natl Acad Sci U S A; 2002 Jul; 99(15):10037-41. PubMed ID: 12096189
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Specificity and effect on apoptosis of Tat antibodies from vaccinated and SHIV-infected rhesus macaques and HIV-infected individuals.
    Belliard G; Romieu A; Zagury JF; Dali H; Chaloin O; Le Grand R; Loret E; Briand JP; Roques B; Desgranges C; Muller S
    Vaccine; 2003 Jul; 21(23):3186-99. PubMed ID: 12804847
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.